An observational study in Chromosome Aberrations, Aneuploidy and Chromosome Deletion, sponsored by 4bases Italia Srl. Recruiting at 2 sites in Italy. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by 4bases Italia Srl · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Aneuploidy with a site in Italy — 1 open to participants now, 1 under way, none of them phase 3. Aneuploidy · Italy.
Among the 11 studies in Aneuploidy with a site in Italy, this one is the only one that started in 2026, is one of 7 observational ones, and was the 11th registered.
75 studies on the registry are indexed under Aneuploidy; 12 are open to participants now.
Browse Aneuploidy studies →1 of the 11 studies in Aneuploidy with a site in Italy is open now.
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 10 Aneuploidy studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 200 is below the median of 290 across 40 observational studies indexed under Aneuploidy.
Median enrollment 346 across the 4 interventional studies, 783 across the 7 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 8 most frequent:
This is the only study on the registry with 4bases Italia Srl as lead sponsor.
4bases Italia Srl has 1 study filed under Aneuploidy — fewer than ten, so there is no comparison to draw.
1 of the studies in Aneuploidy with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT079308324bases Italia SrlStudy to Compare Traditional and Emerging Methods for Structural Variant Analysis in Prenatal, Postnatal, and Hematologic Samples | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Aneuploidy with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study goal is to evaluate an innovative technology, KaryoSolver, which enables molecular karyotype reconstruction, in comparison with reference conventional methods, in terms of:
Presence or absence of clinically detectable structural variants; Type of alteration (aneuploidies, deletions, duplications); Copy number present. KaryoSolver is a software system for reconstructing the molecular karyotype from low-coverage genomic sequencing data using long-read technology.
The expected performance of the device under study is its ability to detect and classify the main clinically detectable structural variants within included samples in a manner consistent with the reference comparators, using a standardizable workflow, competitive turnaround times, and adequate reproducibility.
In particular, the study contributes to demonstrating the following requirements:
75 studies on the registry are indexed under Aneuploidy; 12 are open to participants now.
This study's planned enrollment of 200 is below the median of 290 across 40 observational studies indexed under Aneuploidy.
Browse Aneuploidy studies →This is the only study on the registry with 4bases Italia Srl as lead sponsor.
Compared within Aneuploidy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Chromosome Aberrations. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The biological samples are residual samples already available at the two participating clinical centers. The samples originate from diagnostic workups that have already been completed and were not collected specifically for this study. In particular, residual samples related to prenatal, postnatal constitutional, and oncohematological diagnostics may be used, in accordance with the criteria set forth in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall diagnostic concordance between KaryoSolver and reference methods for the identification of clinically detectable structural variants.
Time frame: through study completion, an average of 1 year
Agreement on the presence/absence of clinically relevant chromosomal alterations between KaryoSolver and reference methods
Time frame: through study completion, an average of 1 year
Agreement by category of identified alteration (aneuploidies, deletions, duplications) between KaryoSolver and reference methods
Time frame: through study completion, an average of 1 year
Percentage of cases correctly classified by KaryoSolver compared to the reference comparator
Time frame: through study completion, an average of 1 year
Intra-run reproducibility of KaryoSolver, assessed as the agreement of results obtained from replicates analyzed in the same session
Time frame: through study completion, an average of 1 year
Inter-run reproducibility of KaryoSolver, assessed as the agreement of results obtained from replicates analyzed in different sessions
Time frame: through study completion, an average of 1 year
Average analytical run time per sample with KaryoSolver compared to reference methods
Time frame: through study completion, an average of 1 year
Average total reporting time/turnaround time with KaryoSolver compared to reference methods.
Time frame: through study completion, an average of 1 year
Reduction in technical/interpretive workload, assessed in terms of man-hours or the number of manual tasks required
Time frame: through study completion, an average of 1 year
Average cost per sample analyzed with KaryoSolver compared to reference methods
Time frame: through study completion, an average of 1 year
Proportion of cases potentially eligible for faster diagnosis using KaryoSolver compared to the standard workflow
Time frame: through study completion, an average of 1 year
Plan to share: No — IPD will not be shared because this is a non-interventional study which does not produce any health outcomes; it is, in fact, a performance study involving IVDs conducted solely for methodological research purposes, with no results being reported for diagnostic or therapeutic purposes.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.